NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 8 June 2021 - 9:30am to 6:16pm

**Location:** Zoom video conference

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice Chair) Present for all items
3. Professor Abdallah Al-Mohammed Present for all items
4. Mr Richard Ballerand Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Justin Daniels Present for items 1 to 5.1.3.
7. Dr Steve Edwards Present for all items
8. Dr Rita Faria Present for items 1 to 5.2.1.
9. Dr Michael Holmes Present for all items
10. Professor Khalida Ismail Present for 1 to 5.1.3.
11. Ms Sumithra Maheswaran Present for items 1 to 5.2.1.
12. Professor G.J. Melendez-Torres Present for all items
13. Mr Hugo Pedder Present for all items
14. Ms Becky Pennington Present for all items
15. Mr Dominic Pivonka Present for all items
16. Ms Pamela Rees Present for all items
17. Dr Mohit Sharma Present for 1 to 5.1.3.
18. Mr Min Ven Teo Present for all items
19. Dr Alice Turner Present for items 4.1.3 to 6
20. Dr Roger Whittaker Present for all items

NICE staff present

Helen Knight, Programme Director Present for items 5 and 6

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Jo Richardson, Technical Advisor Present for all items

Heather Stegenga, Technical Analyst Present for items 1 to 4

George Braileanu, Technical Analyst Present for items 5 and 6

Emily Eaton Turner, HTA Adviser Present for items 5 and 6

Ella Livingstone, Technical Advisor Present for items 1 to 4

Stevie Okoro, Technical analyst - Commercial risk Present for items 5 and 6

Emilene Coventry, Senior Medical Editor Present for items 1 to 4

Sarah Bromley, Senior Medical Editor Present for item 5 and 6

Adam Storrow, Resource Impact Team Present for all items

Matthew Brown, Digital Media Manager Present for items 5 and 6

Laura Marsden, Public Involvement Advisor Present for item 5

Catherine Pank, Assistant Project Manager Present for items 1 to 4

Lucinda Evans, Coordinator Present for items 1 to 4.1 and 5.1

Rosalee Mason, Coordinator Present for item 5.1

Mira Patel, Coordinator Present for all items

Marcia Miller, Administrator Present for item 5

Daniel Greenwood, Assistant Administrator Present for items 1 to 4

Evidence Review Group representatives present

Elisabet Jacobsen, Research Fellow, Aberdeen HTA Group Present for items 1 to 4.1

Dwayne Boyers, Research Fellow, Aberdeen HTA Group Present for items 1 to 4.1

Sophie Beale, Research Associate, Liverpool Reviews and Present for item 5.1

 Implementation Group

Janette Greenhalgh, Senior Research Fellow, Liverpool Present for item 5.1

 Reviews and Implementation Group

James Mahon, Health Economist, Liverpool Reviews Present for items 5.1

 and Implementation Group

Experts present

Professor Peter Clark, CDF Clinical Lead, NHSE&I Present for items 1 to 4

Professor Julia Scarisbrick, Consultant dermatologist, Present for items 4.1.3.

 University Hospitals Birmingham

Dr Robin Lachmann, Consultant in Metabolic Medicine, Present for item 5.1

 UCLH

Dr Hugh Lemonde, Consultant Paediatric Inherited Metabolic Present for item 5.1

 Disease, Evelina Hospital

Mr Malcolm Qualie, Pharmacy Lead, Specialised Present for item 5.1

 Commissioning, NHSE&I

Professor Anita MacDonald, Consultant Dietitian, Birmingham Present for item 5.1

 Children’s Hospital

Ms Sharon Buckley, patient advocate Present for item 5.1

Patient expert nominated by Present for item 5.1

 The National Society for Phenylketonuria

Observers present

Eleanor Donegan, Technical Advisor, NICE Present for items 5 and 6

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Mr Peter Baker, Dr Rishi Hazarika and Ms Sarah Parry.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 6 May 2021.

### Appraisal of Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Recordati Rare Diseases/Helsinn Healthcare SA.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Mr Dominic Pivonka, declared a direct financial interest as his employer, AbbVie, has a treatment being investigated in early phase studies for the treatment of multiple cancers including cutaneous T-cell lymphoma. This is a systemic treatment used in advanced disease and as such, it would not be a competitor for chlormethine gel. It was agreed that this declaration did not constitute a conflict and Mr Pivonka participated in this section of the meeting as usual.
* Professor Julia Scarisbrick, clinical expert, declared direct financial interests as she has undertaken consultancy and advisory work for Recordati and Helsinn. This included a speaker engagement in 2019 for the European Organisation for Research and Treatment of Cancer, medical lectures in the field of MF-CTCL, providing advice on the design of QoL vignette proxy study and healthcare resource utilisation survey designs for the UK and participation on advisory boards and expert group participations. It was agreed that these declarations would not prevent Professor Scarisbrick from providing expert advice to the committee.
* No further conflicts were declared for this appraisal.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr Jane Adam.
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
		1. The committee discussed confidential information submitted for this item.
		2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10481>

### Appraisal of Sapropterin for treating phenylketonuria [ID1475]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from BioMarin.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Anita MacDonald, clinical expert, declared indirect interests as Birmingham Children's Hospital PKU research fund received consultancy fees from Meta Healthcare, Arlo, Nutricia, Apr, Galen and Biomarin. Birmingham Children’s Hospital also received research funds from Nutricia, Vitaflo, Biomarin, APR, Metax, Galen, Mevalia. It was agreed that these declarations would not prevent Professor MacDonald from providing expert advice to the committee.
* Dr Robin Lachmann, clinical expert, declared a direct financial interest as he has an ongoing consultancy agreement with Biomarin to provide input to their PKU gene therapy programme. Dr Lachmann declared a direct financial interest as he is receiving consulting fees from Nestle Health Science regarding their PKU programme (ongoing). Prior to the meeting, Dr Lachmann declared an indirect interest as his institution receives funding from Nutricia. It was agreed that these declarations would not prevent Dr Lachmann from providing expert advice to the committee.
* Prior to the committee meeting, Dr Hugh Lemonde, clinical expert, declared a direct financial interest as he received educational support from Biomarin, enabling attendance to the 1st and 2nd PKU Masterclasses (2017/2018). It was agreed that this declaration would not prevent Dr Lemonde from providing expert advice to the committee.
* Prior to the meeting a patient expert declared an indirect interest and it was agreed that this declaration would not prevent them from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr Jane Adam.
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
		2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10378>

6. Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on 6 July 2021 and will start promptly at 9:30am.